Introduction
Eliglustat (brand name CERDELGA) is a glucosylceramide synthase inhibitor used in the treatment of Gaucher disease (GD). Eliglustat is indicated for the long-term treatment of adult individuals with Gaucher disease type 1 (GD1) who are CYP2D6 normal metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test (1).
Gaucher disease is an autosomal recessive metabolic disorder characterized by accumulation of glucosylceramide (a sphingolipid also known as glucocerebroside) within lysosomes. This is caused by a malfunction of the enzyme acid beta-glucosidase, encoded by the gene GBA. Type 1 GD may present in childhood or adulthood with symptoms including bone disease, hepatosplenomegaly, thrombocytopenia, anemia and lung disease and –– unlike Gaucher types 2 and 3 –– does not directly affect the central nervous system primarily (2). Eliglustat, a ceramide mimic, inhibits the enzyme that synthesizes glucosylceramides (UDP-Glucose Ceramide Glucosyltransferase), thereby reducing the accumulation of these lipids in the lysosome (3).
Eliglustat is broken down to inactive metabolites by CYP2D6 and, to a lesser extent, CYP3A (3). The dosage of eliglustat is based on the individual’s CYP2D6 metabolizer status. Individuals with normal CYP2D6 activity are termed normal metabolizers (NM), those with reduced activity are termed intermediate metabolizers (IM), and if activity is absent, poor metabolizers (PM).
The FDA-approved drug label for eliglustat provides specific dosage guidelines based on their CYP2D6 status and concomitant usage of CYP2D6 or CYP3A inhibitors, and states that hepatic and renal function should also be considered when determining the appropriate dosage (Table 1). The label also states that CYP2D6 ultrarapid metabolizers (UM) may not achieve adequate concentrations of eliglustat for a therapeutic effect, and that for individuals for whom a CYP2D6 genotype cannot be determined, a specific dosage cannot be recommended (1).
Dosing recommendations for eliglustat have also been published by the Dutch Pharmacogenetics Working Group (DPWG) based on CYP2D6 metabolizer type (Table 2) and include dose adjustments for dosing eliglustat with medications that alter CYP2D6 and or CYP3A function (Table 3).
Table 1.
The FDA Recommended Eliglustat Dosage Regimen by CYP2D6 Metabolizer Status (2020)
View in own window
| CYP2D6 metabolizer status | Eliglustat dosage |
|---|
| Ultrarapid metabolizer | May not achieve adequate concentrations |
| Normal metabolizer | 84 mg twice daily |
| Intermediate metabolizer | 84 mg twice daily |
| Poor metabolizer | 84 mg once daily |
| Indeterminate metabolizer | Specific dosage cannot be recommended |
This FDA table is adapted from (1).
Table 2.
The DPWG Recommended Dosing of Eliglustat based on CYP2D6 Phenotype (2018)
View in own window
| Phenotype | Implications for eliglustat therapy | Recommendation |
|---|
| CYP2D6 intermediate metabolizer | This gene variation reduces the conversion of eliglustat to inactive metabolites.
This increases the risk of side effects, such as a (small, dose-dependent) elongation of the QT interval. The CYP3A inhibitors increase this risk even further. | No co-medication –– use the standard dose of 84 mg twice daily.
Co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer: see Table 3. |
| CYP2D6 poor metabolizer | No co-medication –– use a dose of 84 mg once daily.
Co-medication with a CYP3A inhibitor or strong CYP3A inducer: see Table 3. |
| CYP2D6 ultrarapid metabolizer | This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all ultrarapid metabolizers | Eliglustat is contraindicated.
Choose an alternative if possible. |
This DPWG table is adapted from (4) DPWG: Dutch Pharmacogenetics Working Group
Table 3.
The DPWG Adjusted Daily Dosage for Eliglustat 84 mg based on Co-medications and Altered Hepatic Function (2018)
View in own window
| Co-medication(s) | Relative strength of CYP inhibitor/inducer | IM | PM |
|---|
| CYP2D6 inhibitor | Strong1 | Once daily | -- |
| Moderate2 | Once daily# | -- |
| CYP3A inhibitor | Strong3 | Once daily# | CI |
| Moderate4 | Once daily# | CI |
| Weak5 | -- | Once daily# |
| CYP3A inducer | Strong6 | CI | CI |
| CYP2D6 inhibitor with CYP3A inhibitor | Strong1, strong3 | CI | -- |
| Strong1, moderate4 | CI | -- |
| Moderate2, strong3 | CI | -- |
| Moderate2, moderate4 | CI | -- |
CI: Contraindicated, IM: Intermediate Metabolizer, PM: Poor metabolizer
-
1
Strong CYP2D6 inhibitor: for example, paroxetine, fluoxetine, quinidine, bupropion.
-
2
Moderate CYP2D6 inhibitor: for example, duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone.
-
3
Strong CYP3A inhibitor: for example, ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir.
-
4
Moderate CYP3A inhibitor: for example, erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.
-
5
Weak CYP3A inhibitor: amlodipine, cilostazol, fluvoxamine, goldenseal, isoniazid, ranitidine, ranolazine
-
6
Strong CYP3A inducer: rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutin, hypericum
-
#
Individual requires additional monitoring for side effects.
DPWG guidelines available here (4) DPWG: Dutch Pharmacogenetics Working Group
Drug: Eliglustat
Eliglustat (brand name Cerdelga) is an oral substrate reduction therapy, indicated for the long-term treatment of adults with GD1 who are CYP2D6 NMs, IMs or PMs as detected by an FDA-approved test. Eliglustat is a selective substrate inhibitor of glucosylceramide synthase (3, 5). Eliglustat is an oral therapy alternative to injection perfusion enzyme replacement therapy (ERT) for the long-term treatment of GD1.
Gaucher disease is an inborn error of metabolism and lysosomal storage disorder. It is a rare monogenic, autosomal recessive disorder due to biallelic variant of the GBA gene, which encodes the lysosomal enzyme acid beta-glucosidase. Loss of acid beta-glucosidase function results in accumulation of glucosylceramide within the lysosome. Gaucher disease is divided into 3 major clinical types (types 1, 2 and 3) and 2 subtypes (perinatal-lethal form—a subtype of GD type 2 [GD2], and cardiovascular form—a subtype of GD type 3[GD3]). Gaucher disease type 1 is characterized by bone disease, hepatosplenomegaly, thrombocytopenia, anemia, lung disease and a distinct lack of primary CNS disease (in contrast with GD2 and GD3, which present with primary CNS involvement). Gaucher disease type 1 presents in childhood with bone disease occurring in 70–100% of individuals; this bone disease ranges from asymptomatic osteopenia to focal lytic or sclerotic lesions and osteonecrosis. However, bone disease may be the most debilitating aspect of GD1. Liver enlargement and cytopenia are also both very common, nearly universal (2, 6). Biochemical testing of GBA1 enzyme activity in peripheral blood is the gold standard to confirm GD diagnosis; molecular sequencing approaches are limited due to significant sequence identity between GBA and a pseudogene, GBAP (2, 7).
Eliglustat is a ceramide analog that specifically inhibits UDP-glucose ceramide glucosyltransferase, which catalyzes the first glycosylation step in glycosphingolipid biosynthesis (transfer of glucose to ceramide) (3, 7). Inhibition of the ceramide glycosyltransferase reduces the burden of glucosylceramides, which have been shown to accumulate in the lysosomes of GD individuals.
Eliglustat is metabolized primarily by CYP2D6 and, to a lesser extent, CYP3A. No active metabolites are known (3). Metabolized eliglustat is excreted through the urinary and gastrointestinal tracts. The CYP2D6 metabolizer status must be considered when determining the appropriate dosage of eliglustat; NMs, IMs, and PMs with normal hepatic and renal function can take the recommended dosage. Ultrarapid metabolizers “may not achieve adequate concentrations of eliglustat to achieve therapeutic effect.” (1) Dosage levels cannot be recommended for individuals of undetermined CYP2D6 metabolizer status. Individuals who are CYP2D6 NMs concomitantly taking CYP2D6 inhibitors, with moderate or severe hepatic impairment, or mild hepatic impairments and CYP2D6 inhibitor use should not take eliglustat. Both IMs and PMs taking CYP2D6 or CYP3A inhibitors, or both, demonstrating hepatic impairment are also contraindicated from eliglustat use.
Potential risk of cardiac arrhythmias should be considered in individuals taking eliglustat with CYP2D6 or CYP3A inhibitors, with certain metabolizer status and with varying degrees of hepatic impairment. More moderate adverse reactions in individuals during clinical trials included abdominal pain, diarrhea, flatulence, and back/extremity pain and were reported at least once in over 80% of individuals (8). Headache, arthralgia, fatigue and nausea have also been reported at least once in >60% of individuals, but one study found no correlation between CYP2D6 metabolizer status and frequency of these adverse events (8). Real world evidence for use of eliglustat shows most individuals tolerate long-term treatment without adverse effects (9).
Use of eliglustat during pregnancy has not been sufficiently studied to assess drug-associated risks of major birth defects, spontaneous abortion, or other adverse maternal/fetal outcomes. “Women with Gaucher disease type 1 have an increased risk of spontaneous abortion, especially if disease symptoms are not treated and controlled pre-conception and during a pregnancy. Pregnancy may exacerbate existing Gaucher disease type 1 symptoms or result in new disease manifestations. Gaucher disease type 1 manifestations may lead to adverse pregnancy outcomes including, hepatosplenomegaly which can interfere with the normal growth of a pregnancy and thrombocytopenia which can lead to increased bleeding and possible hemorrhage” (1). There are no human data available on the presence of eliglustat in human milk, effects on the breastfed infant, or effects on milk production. Based on animal studies, it is likely that eliglustat would be present in human milk (1).
Eliglustat has not been sufficiently studied for safety and effectiveness in pediatric individuals or subjects over 65. Individuals with renal impairment should be dosed based on their CYP2D6 metabolizer status. Individuals with hepatic impairment should similarly be dosed in light of CYP2D6 metabolizer status and concomitant use of CYP2D6 or CYP3A inhibitors (1).
Gene: CYP2D6
The cytochrome P450 superfamily (CYP450) is a large and diverse group of enzymes that form the major system for metabolizing lipids, hormones, toxins, and drugs in the liver. The CYP450 genes are very polymorphic and can result in decreased, absent, or increased enzyme activity. The CYP2D6 enzyme is responsible for the metabolism of many commonly prescribed drugs, including antidepressants, antipsychotics, analgesics, and beta-blockers.
CYP2D6 Alleles
The CYP2D6 gene on chromosome 22q13.2 is highly polymorphic. Over 100 star (*) alleles have been described and cataloged at the Pharmacogene Variation (PharmVar) Consortium, and each allele is associated with either normal, decreased, or absent enzyme function (Table 4) (10). In addition to the wildtype CYP2D6*1 allele, variant CYP2D6 alleles (or haplotypes) can harbor single nucleotide polymorphisms (SNPs), insertions or deletions, gene conversions, as well as copy number variations.
The combination of CYP2D6 alleles that a person has is used to determine their diplotype (for example, CYP2D6 *4/*4). Based on function, each allele can be assigned an activity score from 0 to 1, which in turn is often used to assign a phenotype (for example, CYP2D6 poor metabolizer). However, the activity score system is not standardized across clinical laboratories or CYP2D6 genotyping platforms. The CPIC revised their activity scoring guidelines in October 2019 to promote harmonization. The CYP2D6 phenotype is defined by the sum of the 2 allele activity scores, which is most commonly in the range of 0 to 3.0 (11):
An UM has an activity score greater than 2.25
A NM phenotype has an activity score of 1.25–2.25
An IM has an activity score of >0–1.25
A PM has an activity score of 0 (
14)
Table 4.
Activity Status of Selected CYP2D6 Alleles
View in own window
| Allele type | CYP2D6 alleles |
|---|
| Normal function | *1, *2, *27, *33 |
| Decreased function | *10, *17, *41, *49 |
| No function | *3, *4, *5, *6, *36 |
For a comprehensive list of CYP2D6 alleles, please See PharmVar.
The
CYP2D6*1 allele is considered the wildtype allele when no variants are detected and is associated with normal enzyme activity and the “normal metabolizer” phenotype. In addition, the CYP2D6*2, *27, and *33 alleles are also considered to have near-normal activity.
Other CYP2D6 alleles include variants that produce a non-functioning enzyme (for example, *3, *4, *5, and *6) (12, 13, 14, 15) or an enzyme with decreased activity (for example, *10, *17, and *41) (16, 17, 18) (see Table 4). There are large inter-ethnic differences in the frequency of these alleles, with *3, *4, *5, *6, and *41 being more common in Caucasians, *17 more common in Africans, and *10 more common in Asians (19).
Allele Frequencies Vary between Populations
Among Asians and in individuals of Asian descent, only approximately 50% of CYPD6 alleles are normal function, and the frequency of CYP2D6 duplications is as high as 45%, although this may have been overestimated by not accounting for tandem hybrid alleles (for example, *36+*10) (20). Other studies of a US individual population suggested less than 50% of alleles detected within Asian-descent individuals are normal function alleles in a single copy, with 30% of alleles arising from structural variants (duplications or deletions) (21). Common no-function variants are CYP2D6*36 and CYP2D6*4 (21). Both these alleles contain the variant “c.100C>T” (see Allele Nomenclature table) (19, 20, 22, 23). The CYP2D6*36 allele is the result of a gene conversion event with the pseudogene CYP2D7 (24). This no-function allele is most commonly found in individuals of Asian ancestry (21).
Among Africans and African-Americans, only approximately 50% of CYP2D6 alleles are normal function (12, 18, 19, 25). African-Americans also have been found to have a higher frequency of no-function structural variants or decreased function single-copy variant alleles versus Caucasian or Hispanic-Americans (21).
Middle Eastern countries show a great diversity in phenotypic and allelic distribution for CYP2D6 (26), though on average, these individuals show a lower frequency of PM phenotypes (0.91%) and higher UM phenotypes (11.2%) than other ethnicities (Note: Oceania and Middle Eastern ethnicities combined in this study) (27).
Among European countries, there is diversity of allelic distribution (28). Gene duplications were more common in the south-eastern countries (Greece, Turkey: 6%) and less common in north-western countries (Sweden and Denmark, <1%). Meanwhile, CYP2D6*4 and *5 alleles were generally more common in the north and less common in the south. (28) Worldwide CYP2D6 genotype and phenotype frequencies have been catalogued and recently published (27).
CYP2D6 Phenotype
CYP2D6 Phenotype Frequencies Vary between Populations
Normal metabolizers: Approximately 77–92% of individuals have 2 normal function alleles (*1 or *2), or one normal function allele and one decreased function allele. These individuals are “normal metabolizers” and are most likely to have a phenotypically normal response to the drug.
Intermediate metabolizers: Approximately 2–11% of individuals are IMs—they have either 2 decreased function alleles or one normal or decreased function and one no allele (27). A study of a diverse US urban population of children found that roughly 8% of subjects were IMs (29), Within the US, it has been observed that individuals of African or Asian descent were most likely to be classified as IMs (20–28% of population by ethnicity) (21).
Poor metabolizers: Approximately 5–10% of individuals are PMs—they have 2 no alleles (30). The PMs are more commonly found in European Caucasians and their descendants. The no CYP2D6*4 and *5 alleles largely account for the PM phenotype in these populations (14, 17, 31). It should be noted that the frequency of PMs can be much lower in certain populations including East Asian, Oceania and Middle Eastern (27). Studies of US multi-ethnic populations have estimated the prevalence of PM to be between 1.5–5.7% (21, 29).
Ultrarapid metabolizers: Individuals who are UMs have at least 3 copies of the CYP2D6 gene. The UM phenotype has been estimated to be present in 1–2% of individuals, but the prevalence varies widely in different populations. It is estimated to be present in up to 28% of North Africans, Ethiopians, and Arabs; up to 10% in Caucasians; 3% in African-Americans, and up to 1% in Hispanics, Chinese, and Japanese (30, 32). The UMs made up 9% of subjects in an urban multi-ethnic population with a large portion of Hispanic/Latino subjects (29). A larger study of US individuals predicted a UM phenotype in only 2.2% of individuals, regardless of ethnicity (21).
Linking Gene Variation with Treatment Response
Genetic variation in the CYP2D6 gene can influence whether an individual achieves adequate concentrations of eliglustat and therapeutic benefit (namely, CYP2D6 ultrarapid metabolizers) or is at an increased risk of adverse events (namely, CYP2D6 poor metabolizers). Eliglustat dose, metabolizer status/genotype and concomitant CYP inhibitor medication use should all be considered in assessing potential risk of cardiac arrhythmias. Conditions that decrease the clearance of eliglustat put individuals in this elevated risk category (namely, hepatic impairment, CYP2D6 IMs or PMs taking CYP inhibitors), for complete information please see (1).
Six GD individuals in the International Collaborative Gaucher Group Gaucher Registry who were known UMs voluntarily reported their 1–3 year outcomes after taking eliglustat. This included individuals who had been on ERT and switched to eliglustat as well as some who were treatment naive. For these individuals, the reported dosages were 84 mg 3 times daily (4 individuals) or twice daily (2 individuals). Four of the 6 individuals maintained hemoglobin concentration and platelet counts within the therapeutic goal range after 2 years; however, one individual developed anemia and another developed moderate thrombocytopenia. One individual reported discontinuation of eliglustat (rationale unclear). Adverse events and reasons for discontinuation of therapies are not recorded within the Registry; however, very few individuals of any metabolizer status discontinued treatment with eliglustat over the course of this study (22/231, 9%). (9)
Genetic Testing
The NIH Genetic Testing Registry provides examples of the genetic tests that are available for eliglustat response and for the CYP2D6 gene.
The CYP2D6 is a particularly complex gene that is difficult to genotype due to highly homologous neighboring pseudogenes, as well as the large number of variants and the presence of gene deletions, duplications, and multiplications. The complexity of genetic variation complicates making a correct determination of CYP2D6 genotype.
Targeted genotyping typically includes up to 30 variant CYP2D6 alleles (over 100 alleles have been identified so far). Test results are reported as a diplotype, such as CYP2D6 *1/*1. However, it is important to note that the number of variants tested can vary among laboratories, which can result in diplotype result discrepancies between testing platforms and laboratories (33).
A result for copy number, if available, is also important when interpreting CYP2D6 genotyping results. Gene duplications and multiplications can be denoted by “xN”, for example: CYP2D6*1xN with xN representing the number of CYP2D6 gene copies. Note representation of duplications is also not standardized among laboratories.
If the test results include an interpretation of the individual’s predicted metabolizer phenotype, such as “CYP2D6 *1/*1, normal metabolizer”, this may be confirmed by checking the diplotype and assigning an activity score to each allele (for example, 0 for no, 0.5 for decreased function, and 1.0 for each copy of a normal function allele, Table 4). See the CYP2D6 alleles section above for more information.
Therapeutic Recommendations based on Genotype
This section contains excerpted1
information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.
2018 Statement from the US Food and Drug Administration (FDA):
The recommended dosage of Eliglustat in adults is based on the patient's CYP2D6 metabolizer status.
[…]
Reduce dosage frequency of Eliglustat 84 mg to once daily in CYP2D6 NMs and IMs with or without hepatic impairment taking CYP2D6 or CYP3A inhibitors.
Table [5]
: Recommended Dosage of Eliglustat: 84 mg Once Daily based on CYP2D6 Metabolizer, Hepatic Impairment Status, and Concomitant CYP Inhibitors
View in own window
| CYP2D6 Metabolizer Status | Hepatic Impairment Status | Concomitant CYP Inhibitor |
|---|
| NMs | Without Hepatic Impairment | Taking a strong or moderate CYP2D6 inhibitor
Taking a strong or moderate CYP3A inhibitor |
| Mild (Child-Pugh Class A) Hepatic Impairment | Taking a weak CYP2D6 inhibitor
Taking a strong, moderate, or weak CYP3A inhibitor |
| IMs | Without hepatic involvement | Taking a strong or moderate CYP2D6 inhibitor |
4
CONTRAINDICATIONS
Eliglustat is contraindicated in the following patients based on CYP2D6 metabolizer status due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals.
NMs
Taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
Moderate or severe hepatic impairment
Mild hepatic impairment and taking a strong or moderate CYP2D6 inhibitor
IMs
PMs
7 DRUG INTERACTIONS
7.1 Effect of other drugs on Eliglustat
Coadministration of Eliglustat with:
CYP2D6 or CYP3A inhibitors may increase eliglustat concentrations which may increase the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac interval.
strong CYP3A inducers decreases eliglustat concentrations which may reduce efficacy.
Table [6]
: Prevention and Management Strategies of Drug Interactions Affecting eliglustat based on CYP2D6 Metabolizer status and Concomitant Interacting drug
View in own window
| Concomitant Drug(s) | CYP2D6 Metabolizer Status |
|---|
| NMs | IMs | PMs |
|---|
| CYP2D6 Inhibitor |
| Strong | Reduce frequency of eliglustat 84mg to once daily | Continue eliglustat 84mg once daily* |
| Moderate |
| Weak | Continue eliglustat 84mg twice daily |
| CYP3A Inhibitor |
| Strong | Reduce frequency of eliglustat 84 mg to once daily | Contraindicated |
| Moderate | Avoid coadministration. |
| Weak | Continue eliglustat 84mg twice daily | Avoid coadministration. |
| CYP2D6 Inhibitor Concomitantly with a strong CYP3A Inhibitor |
| Strong | Contraindicated |
| Moderate |
| CYP2D6 Inhibitor Concomitantly with a moderate CYP3A Inhibitor |
| Strong | Contraindicated | Avoid coadministration |
| Moderate |
| CYP3A Inducer |
| Strong | Avoid coadministration |
- *
No effect of CYP2D6 inhibitor due to little or no CYP2D6 activity in CYP2D6 PMs.
8
Use In Specific Populations
8.6 Renal Impairment
Use eliglustat in patients with renal impairment based on the patient's CYP2D6 metabolizer status
NMs
Avoid eliglustat in patients with end-stage renal disease (ESRD) (estimated creatinine clearance (eCLcr) less than 15 mL/min not on dialysis or requiring dialysis).
No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCLcr at least 15 mL/min).
IMs and PMs
Avoid eliglustat in patients with any degree of renal impairment.
8.7 Hepatic Impairment
Use eliglustat in patients with hepatic impairment based on CYP2D6 metabolizer status and concomitant use of CYP2D6 or CYP3A inhibitors
NMs
Eliglustat is contraindicated in patients with [see Contraindications]:
severe (Child-Pugh Class C) hepatic impairment
moderate (Child-Pugh Class B) hepatic impairment
mild (Child-Pugh Class A) hepatic impairment taking a strong or moderate CYP2D6 inhibitor
Reduce dosage frequency of eliglustat 84 mg to once daily [see Dosage and Administration] in patients with mild hepatic impairment taking:
No dosage adjustment is recommended in patients with mild hepatic impairment, unless otherwise specified above.
IMs and PMs
Eliglustat is contraindicated in patients with any degree of hepatic impairment [see Contraindications].
Please review the complete therapeutic recommendations that are located here: (1).
2018 Summary of recommendations from the Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Association for the Advancement of Pharmacy (KNMP)
CYP2D6 UM:
Eliglustat is contra-indicated.
- 1.
choose an alternative if possible
CYP2D6 IM:
Recommendation:
Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.
Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):
- 1.
use a dose of 84 mg eliglustat 1x daily
Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):
- 1.
consider a dose of 84 mg eliglustat 1x daily
- 2.
be alert to side effects
Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):
-1. choose an alternative if possible
CYP2D6 PM:
Recommendation:
Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):
Eliglustat is contra-indicated.
- 1.
choose an alternative if possible
Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):
Eliglustat is not recommended.
- 1.
choose an alternative if possible
Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine [amlodipine], cilostazole [cilostazol], fluvoxamine, goldenseal, isoniazide [isoniazid], ranitidine, ranolazine):
- 1.
choose an alternative for the weak CYP3A inhibitor if possible
- 2.
if an alternative is not an option:
- 1.
use a dose of 84 mg eliglustat 1x daily
- 2.
be alert to side effects
Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum):
Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.
- 1.
choose an alternative if possible
Please review the complete therapeutic recommendations that are located here:(
4
).
Nomenclature for Selected CYP2D6 Alleles
View in own window
-
[1]
In the literature, 1023C>T is also referred to as 1111C>T
-
[2]
In the literature, 2851C>T is also referred to as 2938C>T
- [3]
CYP2D6*36 is a gene conversion with CYP2D7; variants provided here are from the Pharmacogene Variation Consortium.
Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting (34).
Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS).
Nomenclature for Cytochrome P450 enzymes is available from the Pharmacogene Variation (PharmVar) Consortium.
Acknowledgments
The authors would like to thank Jeff Szer, B Med Sc, MB BS, FRACP, Professor University of Melbourne, Clinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia and Pramod K. Mistry, MD, PhD, FRCP, FAASLD, Professor of Medicine and Pediatrics, Professor of Cellular & Molecular Physiology, Yale School of Medicine, New Haven, CT, USA for reviewing this summary.
References
- 1.
- 2.
Pastores, G.M. and D.A. Hughes,
Gaucher Disease, in
GeneReviews (R) [Internet], M.P. Adam, et al., Editors. 2018, University of Washington, Seattle: Seattle (WA). [
PMC free article: PMC1269] [
PubMed: 20301446]
- 3.
- 4.
Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharamcogenetic Guidelines [Internet]. Netherlands. Eliglustat - CYP2D6 [Cited June 2020]. Available from:
http://kennisbank.knmp.nl.
- 5.
Belmatoug N., Di Rocco M., Fraga C., Giraldo P., et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Eur J Intern Med. 2017;37:25–32. [
PubMed: 27522145]
- 6.
Online Mendelian Inheritance in Man, OMIM (R). 22 May 2020; Available from:
https://omim.org/ - 7.
- 8.
Peterschmitt M.J., Freisens S., Underhill L.H., Foster M.C., et al. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Orphanet J Rare Dis. 2019;14(1):128. [
PMC free article: PMC6555985] [
PubMed: 31174576]
- 9.
Mistry P.K., Balwani M., Charrow J., Kishnani P., et al. Real-world effectiveness of eliglustat in treatment-naive and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Am J Hematol. 2020;95(9):1038–1046. [
PMC free article: PMC7497238] [
PubMed: 32438452]
- 10.
Reny J.L., Fontana P. Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?
Expert Opin Pharmacother. 2015;16(4):449–52. [
PubMed: 25495963]
- 11.
- 12.
Yokota H., Tamura S., Furuya H., Kimura S., et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
Pharmacogenetics. 1993;3(5):256–63. [
PubMed: 8287064]
- 13.
- 14.
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Pharmacogenomics J. 2005;5(1):6–13. [
PubMed: 15492763]
- 15.
- 16.
- 17.
- 18.
- 19.
Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.
Pharmacogenomics. 2002;3(2):229–43. [
PubMed: 11972444]
- 20.
Ramamoorthy A., Flockhart D.A., Hosono N., Kubo M., et al. Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays.
Pharmacogenet Genomics. 2010;20(7):451–4. [
PMC free article: PMC4411953] [
PubMed: 20421845]
- 21.
- 22.
Wu X., Yuan L., Zuo J., Lv J., et al. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Eur J Clin Pharmacol. 2014;70(1):57–63. [
PubMed: 24077935]
- 23.
Hosono N., Kato M., Kiyotani K., Mushiroda T., et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection.
Clin Chem. 2009;55(8):1546–54. [
PubMed: 19541866]
- 24.
Gaedigk A., Bradford L.D., Alander S.W., Leeder J.S. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Drug Metab Dispos. 2006;34(4):563–9. [
PubMed: 16415111]
- 25.
Sistonen J., Sajantila A., Lao O., Corander J., et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.
Pharmacogenet Genomics. 2007;17(2):93–101. [
PubMed: 17301689]
- 26.
- 27.
- 28.
- 29.
Virbalas J., Morrow B.E., Reynolds D., Bent J.P., et al. The Prevalence of Ultrarapid Metabolizers of Codeine in a Diverse Urban Population.
Otolaryngol Head Neck Surg. 2019;160(3):420–425. [
PubMed: 30322340]
- 30.
- 31.
Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Pharmacol Ther. 2007;116(3):496–526. [
PubMed: 18001838]
- 32.
- 33.
Hicks J.K., Swen J.J., Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.
Curr Drug Metab. 2014;15(2):218–32. [
PubMed: 24524666]
- 34.
Kalman L.V., Agundez J., Appell M.L., Black J.L., et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
Clin Pharmacol Ther. 2016;99(2):172–85. [
PMC free article: PMC4724253] [
PubMed: 26479518]
-
1
The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labeled all formulations containing the generic drug. Certain terms, genes and genetic variants may be corrected in accordance with nomenclature standards, where necessary. We have given the full name of abbreviations, shown in square brackets, where necessary.
1 and